Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)
CNY 23.75
(-0.88%)
CNY 23.75
(-0.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 859.12 Million CNY | -52.25% |
| 2022 | 1.67 Billion CNY | 87.05% |
| 2021 | 921.21 Million CNY | -6.63% |
| 2020 | 890.7 Million CNY | 52.51% |
| 2019 | 621 Million CNY | 35.6% |
| 2018 | 485.75 Million CNY | 49.78% |
| 2017 | 320.52 Million CNY | 62.71% |
| 2016 | 198.29 Million CNY | 44.95% |
| 2015 | 135.61 Million CNY | 3.02% |
| 2014 | 132.34 Million CNY | 56.7% |
| 2013 | 84.93 Million CNY | 46.57% |
| 2012 | 54.88 Million CNY | 133.45% |
| 2011 | 25.64 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 94.03 Million CNY | -59.75% |
| 2024 Q2 | 201.94 Million CNY | -29.07% |
| 2024 Q1 | 266.34 Million CNY | 102.46% |
| 2023 FY | - CNY | -52.25% |
| 2023 Q1 | 241.35 Million CNY | 478.21% |
| 2023 Q4 | 101.91 Million CNY | 57.39% |
| 2023 Q2 | 161.58 Million CNY | -33.05% |
| 2023 Q3 | 64.75 Million CNY | -59.93% |
| 2022 Q2 | 239.66 Million CNY | -78.92% |
| 2022 Q1 | 1.13 Billion CNY | 4754.61% |
| 2022 Q4 | 41.74 Million CNY | -50.44% |
| 2022 Q3 | 84.22 Million CNY | -64.86% |
| 2022 FY | - CNY | 87.05% |
| 2021 Q4 | 23.42 Million CNY | -58.43% |
| 2021 Q1 | 190.03 Million CNY | -0.12% |
| 2021 Q2 | 474.48 Million CNY | 149.68% |
| 2021 FY | - CNY | -6.63% |
| 2021 Q3 | 56.34 Million CNY | -88.13% |
| 2020 Q3 | 136.66 Million CNY | -68.01% |
| 2020 Q2 | 427.27 Million CNY | 252.47% |
| 2020 Q1 | 121.22 Million CNY | -33.41% |
| 2020 FY | - CNY | 52.51% |
| 2020 Q4 | 190.25 Million CNY | 39.22% |
| 2019 Q3 | 105.7 Million CNY | -40.1% |
| 2019 Q2 | 176.46 Million CNY | 84.71% |
| 2019 FY | - CNY | 35.6% |
| 2019 Q4 | 182.03 Million CNY | 72.22% |
| 2019 Q1 | 95.53 Million CNY | -22.52% |
| 2018 Q3 | 77.49 Million CNY | -39.32% |
| 2018 Q2 | 127.71 Million CNY | 41.17% |
| 2018 Q1 | 90.46 Million CNY | 38.57% |
| 2018 FY | - CNY | 49.78% |
| 2018 Q4 | 123.3 Million CNY | 59.1% |
| 2017 Q4 | 65.28 Million CNY | -21.1% |
| 2017 Q1 | 38.09 Million CNY | -38.69% |
| 2017 Q2 | 92.39 Million CNY | 142.55% |
| 2017 FY | - CNY | 62.71% |
| 2017 Q3 | 82.74 Million CNY | -10.44% |
| 2016 FY | - CNY | 44.95% |
| 2016 Q4 | 62.13 Million CNY | 98.49% |
| 2016 Q3 | 31.3 Million CNY | -41.72% |
| 2016 Q2 | 53.71 Million CNY | 98.99% |
| 2016 Q1 | 26.99 Million CNY | -24.22% |
| 2015 FY | - CNY | 3.02% |
| 2015 Q4 | 35.62 Million CNY | 95.47% |
| 2015 Q3 | 18.22 Million CNY | -56.79% |
| 2015 Q2 | 42.17 Million CNY | 88.95% |
| 2015 Q1 | 22.32 Million CNY | -38.66% |
| 2014 Q1 | 24.54 Million CNY | 0.0% |
| 2014 Q4 | 36.38 Million CNY | 32.55% |
| 2014 Q3 | 27.45 Million CNY | -13.47% |
| 2014 Q2 | 31.72 Million CNY | 29.22% |
| 2014 FY | - CNY | 56.7% |
| 2013 FY | - CNY | 46.57% |
| 2012 FY | - CNY | 133.45% |
| 2011 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.86 Billion CNY | 53.816% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.84 Billion CNY | 69.818% |
| Dirui Industrial Co.,Ltd. | 288.83 Million CNY | -197.443% |
| Beijing Strong Biotechnologies, Inc. | 697.99 Million CNY | -23.086% |
| Medicalsystem Biotechnology Co., Ltd. | 475.01 Million CNY | -80.865% |
| Maccura Biotechnology Co.Ltd | 651.98 Million CNY | -31.771% |
| Guangdong Hybribio Biotech Co.,Ltd. | 236.08 Million CNY | -263.911% |
| BGI Genomics Co., Ltd. | 714.86 Million CNY | -20.181% |
| Amoy Diagnostics Co., Ltd. | 352.59 Million CNY | -143.657% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -59 Million CNY | 1555.924% |